Return on Equity (ROE)
since 2012
Difficulty: Beginner
Calculation
AbbVie Inc., ROE, long-term trends, calculation
| ROE | = | 100 | × | Net earnings1 | ÷ | Stockholders' equity1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2012 | 156.85% | = | 100 | × | 5,275 | ÷ | 3,363 |
| Dec 31, 2013 | 91.90% | = | 100 | × | 4,128 | ÷ | 4,492 |
| Dec 31, 2014 | 101.84% | = | 100 | × | 1,774 | ÷ | 1,742 |
| Dec 31, 2015 | 130.39% | = | 100 | × | 5,144 | ÷ | 3,945 |
| Dec 31, 2016 | 128.41% | = | 100 | × | 5,953 | ÷ | 4,636 |
| Dec 31, 2017 | 104.16% | = | 100 | × | 5,309 | ÷ | 5,097 |
1 USD $ in millions
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Competitors
AbbVie Inc., ROE, long-term trends, comparison to competitors
| AbbVie Inc. | Abbott Laboratories | Allergan PLC | Amgen Inc. | Biogen Inc. | Bristol-Myers Squibb Co. | Celgene Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2012 | 156.85% | 22.32% | 2.54% | 22.80% | 19.82% | 14.39% | 25.57% | 27.69% | 27.84% | 16.74% | 11.63% | 17.93% | 60.24% |
| Dec 31, 2013 | 91.90% | 10.23% | -7.87% | 23.00% | 21.60% | 16.91% | 25.94% | 26.57% | 27.05% | 18.68% | 8.85% | 28.83% | 21.74% |
| Dec 31, 2014 | 101.84% | 10.61% | -5.76% | 20.01% | 27.15% | 13.49% | 30.65% | 15.55% | 78.45% | 23.40% | 24.50% | 12.81% | 13.69% |
| Dec 31, 2015 | 130.39% | 20.85% | 5.11% | 24.71% | 37.84% | 10.97% | 27.07% | 16.53% | 97.70% | 21.66% | 9.94% | 10.75% | 17.40% |
| Dec 31, 2016 | 128.41% | 6.82% | 19.65% | 25.85% | 30.50% | 27.55% | 30.29% | 19.54% | 71.48% | 23.49% | 9.78% | 12.12% | 20.13% |
| Dec 31, 2017 | 104.16% | 1.54% | -5.59% | 7.84% | 20.13% | 8.58% | 42.48% | -1.76% | 22.64% | 2.16% | 6.97% | 29.47% | 19.51% |
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Pharmaceuticals & Biotechnology Sector
AbbVie Inc., ROE, long-term trends, comparison to Pharmaceuticals & Biotechnology sector
| AbbVie Inc. | Pharmaceuticals & Biotechnology | |
|---|---|---|
| Dec 31, 2012 | 156.85% | 19.59% |
| Dec 31, 2013 | 91.90% | 20.31% |
| Dec 31, 2014 | 101.84% | 20.07% |
| Dec 31, 2015 | 130.39% | 19.94% |
| Dec 31, 2016 | 128.41% | 22.76% |
| Dec 31, 2017 | 104.16% | 10.97% |
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Health Care Industry
AbbVie Inc., ROE, long-term trends, comparison to Health Care industry
| AbbVie Inc. | Health Care | |
|---|---|---|
| Dec 31, 2012 | 156.85% | 18.13% |
| Dec 31, 2013 | 91.90% | 18.69% |
| Dec 31, 2014 | 101.84% | 18.41% |
| Dec 31, 2015 | 130.39% | 17.51% |
| Dec 31, 2016 | 128.41% | 20.08% |
| Dec 31, 2017 | 104.16% | 12.07% |
Source: Based on data from AbbVie Inc. Annual Reports